Overview

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Status:
Terminated

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin & capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Antibodies, Monoclonal
Capecitabine
Cisplatin
Epirubicin
Rilotumumab